• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞因子血液滤过反应与 COVID-19。

Cytokine Blood Filtration Responses in COVID-19.

机构信息

Department of Medical Equipment Technology, College of Applied Medical Science, Majmaah University, Majmaah, Saudi Arabia.

Department of Medical Equipment Technology, College of Applied Medical Science, Majmaah University, Majmaah, Saudi Arabia,

出版信息

Blood Purif. 2021;50(2):141-149. doi: 10.1159/000508278. Epub 2020 May 28.

DOI:10.1159/000508278
PMID:32464624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7490911/
Abstract

The real issue with the COVID-19 pandemic is that a rapidly increasing number of patients with life-threatening complications are admitted in hospitals and are not well-administered. Although a limited number of patients use the intensive care unit (ICU), they consume medical resources, safety equipment, and enormous equipment with little possibility of rapid recovery and ICU discharge. This work reviews effective methods of using filtration devices in treatment to reduce the level of various inflammatory mediators and discharge patients from the ICU faster. Extracorporeal technologies have been reviewed as a medical approach to absorb cytokines. Although these devices do not kill or remove the virus, they are a promising solution for treating patients and their faster removal from the ICU, thus relieving the bottleneck.

摘要

COVID-19 大流行的真正问题是,越来越多患有危及生命并发症的患者被送往医院,但医院管理不善。尽管只有少数患者使用重症监护病房(ICU),但他们消耗了医疗资源、安全设备和大量设备,而且几乎不可能迅速康复并离开 ICU。这项工作综述了使用过滤设备进行治疗的有效方法,以降低各种炎症介质的水平,并更快地将患者从 ICU 中出院。体外技术已被视为一种吸收细胞因子的医疗方法。尽管这些设备不能杀死或清除病毒,但它们是治疗患者的有前途的解决方案,并且可以更快地将他们从 ICU 中移除,从而缓解瓶颈问题。

相似文献

1
Cytokine Blood Filtration Responses in COVID-19.细胞因子血液滤过反应与 COVID-19。
Blood Purif. 2021;50(2):141-149. doi: 10.1159/000508278. Epub 2020 May 28.
2
Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.早期血液灌流去除细胞因子可能有助于预防 COVID-19 感染患者插管。
Blood Purif. 2021;50(2):257-260. doi: 10.1159/000509107. Epub 2020 Jun 26.
3
Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm.血液灌流作为治疗重症新冠病毒肺炎细胞因子风暴患者的潜在疗法
Blood Purif. 2021;50(3):405-407. doi: 10.1159/000511391. Epub 2020 Nov 10.
4
Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.体外治疗(HA-380 联合高容量血液滤过)在重症 COVID-19 患者中早期清除细胞因子可能预防急性呼吸窘迫综合征进展:病例报告。
Blood Purif. 2021;50(4-5):575-577. doi: 10.1159/000512982. Epub 2020 Dec 2.
5
Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum.冠状病毒疫情与重症监护中的体外治疗:欲求和平,先备战。
Blood Purif. 2020;49(3):255-258. doi: 10.1159/000507039. Epub 2020 Mar 13.
6
Reinforcing the Team: A Call to Critical Care Nephrology in the COVID-19 Epidemic.加强团队力量:新冠疫情下对重症监护肾脏病学的呼吁
Blood Purif. 2021;50(3):275-278. doi: 10.1159/000510881. Epub 2020 Sep 21.
7
Immunomodulation using CONVEHY® for COVID-19: from the storm to the cytokine anticyclone.使用CONVEHY®对新型冠状病毒肺炎进行免疫调节:从风暴到细胞因子反气旋
Rev Esp Anestesiol Reanim (Engl Ed). 2021 Feb;68(2):107-112. doi: 10.1016/j.redar.2020.08.001. Epub 2020 Aug 29.
8
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.双盲、随机、对照临床试验评估同种异体间充质基质细胞治疗 COVID-19 所致急性呼吸窘迫综合征患者的疗效(COVID-AT):一项随机对照试验的研究方案的结构总结。
Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1.
9
The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China.中国武汉一项回顾性、多中心、描述性研究:细胞因子释放综合征危重症 COVID-19 患者连续性肾脏替代治疗的效果。
Aging (Albany NY). 2021 Apr 3;13(7):9243-9252. doi: 10.18632/aging.202838.
10
Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis.使用介质吸附膜的持续高效每日透析滤过(SHEDD-fA)治疗严重脓毒症患者
Contrib Nephrol. 2011;173:172-181. doi: 10.1159/000329057. Epub 2011 Aug 8.

引用本文的文献

1
Efficacy of additional hemoperfusion in hospitalized patients with severe to critical COVID-19 disease.住院的重症至危重症 COVID-19 患者行血液灌流治疗的疗效。
Sci Rep. 2024 Jul 31;14(1):17651. doi: 10.1038/s41598-024-68592-4.
2
Retrospective evaluation of 22 dogs with leptospirosis treated with extracorporeal renal replacement therapies (2018-2021).回顾性评估 22 例接受体外肾替代治疗的钩端螺旋体病犬(2018-2021 年)。
J Vet Intern Med. 2024 Mar-Apr;38(2):1051-1059. doi: 10.1111/jvim.16998. Epub 2024 Feb 9.
3
Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.脓毒症和新冠肺炎中的血液净化:细胞因子和内毒素血液吸附有哪些新进展。
J Anesth Analg Crit Care. 2022 Apr 4;2(1):15. doi: 10.1186/s44158-022-00043-w.
4
Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.用于 COVID-19 管理的血液过滤系统:细胞因子风暴治疗的新方法。
Front Immunol. 2023 Apr 21;14:1064459. doi: 10.3389/fimmu.2023.1064459. eCollection 2023.
5
Factors Associated with Length of Hospital Stay among COVID-19 Patients in Saudi Arabia: A Retrospective Study during the First Pandemic Wave.沙特阿拉伯新冠肺炎患者住院时间的相关因素:首次疫情高峰期间的一项回顾性研究
Healthcare (Basel). 2022 Jun 27;10(7):1201. doi: 10.3390/healthcare10071201.
6
Cytokine Adsorption in Critically Ill COVID-19 Patients, a Case-Control Study.危重症 COVID-19 患者细胞因子吸附:一项病例对照研究。
J Intensive Care Med. 2022 Sep;37(9):1223-1228. doi: 10.1177/08850666221085185. Epub 2022 Mar 11.
7
A Case of COVID-19-Associated Pediatric Multisystem Inflammatory Syndrome in Shock Managed by Cytokine Filtration.1例采用细胞因子滤过治疗的新冠病毒相关小儿多系统炎症综合征休克病例
Case Rep Pediatr. 2022 Feb 2;2022:3373289. doi: 10.1155/2022/3373289. eCollection 2022.
8
Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients.体外血液净化与危重症 COVID-19 患者的生化和临床变量的改善有关。
Ther Apher Dial. 2022 Apr;26(2):316-329. doi: 10.1111/1744-9987.13730. Epub 2021 Sep 16.
9
Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia.沙特阿拉伯 COVID-19 患者的临床特征和死亡预测因素。
J Infect Public Health. 2021 Aug;14(8):994-1000. doi: 10.1016/j.jiph.2021.06.005. Epub 2021 Jun 11.
10
Hemadsorption as a Treatment Option for Multisystem Inflammatory Syndrome in Children Associated With COVID-19. A Case Report.血液吸附治疗 COVID-19 相关儿童多系统炎症综合征 1 例报告。
Front Immunol. 2021 Jun 1;12:665824. doi: 10.3389/fimmu.2021.665824. eCollection 2021.

本文引用的文献

1
Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.新型冠状病毒肺炎患者疾病严重程度与炎症相关参数的相关性分析:一项回顾性研究。
BMC Infect Dis. 2020 Dec 21;20(1):963. doi: 10.1186/s12879-020-05681-5.
2
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).新型冠状病毒病(COVID-19)患者 T 细胞减少和功能耗竭。
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
3
Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.在重症 2019 冠状病毒病患者中,可检测到的血清严重急性呼吸综合征冠状病毒 2 病毒载量(RNAemia)与显著升高的白细胞介素 6 水平密切相关。
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942. doi: 10.1093/cid/ciaa449.
4
Clinical trials on drug repositioning for COVID-19 treatment.用于治疗新冠肺炎的药物重新定位的临床试验。
Rev Panam Salud Publica. 2020 Mar 20;44:e40. doi: 10.26633/RPSP.2020.40. eCollection 2020.
5
Multiscale Biofluidic and Nanobiotechnology Approaches for Treating Sepsis in Extracorporeal Circuits.用于治疗体外循环中脓毒症的多尺度生物流体和纳米生物技术方法。
Biochip J. 2020;14(1):63-71. doi: 10.1007/s13206-020-4106-6. Epub 2020 Mar 12.
6
Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum.冠状病毒疫情与重症监护中的体外治疗:欲求和平,先备战。
Blood Purif. 2020;49(3):255-258. doi: 10.1159/000507039. Epub 2020 Mar 13.
7
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
8
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
9
Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock.血液灌流联合脉冲高容量血液滤过对感染性休克的临床疗效
Medicine (Baltimore). 2020 Feb;99(9):e19058. doi: 10.1097/MD.0000000000019058.
10
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.冠状病毒病(COVID-19)疫情的流行病学和发病机制。
J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.